Oxford BioTherapeutics has announced the appointment of Dr Keith E Wilson as Chief Scientific Officer. Dr Wilson joins from AbbVie where he was the company’s Global Leader for Antibody Drug Conjugates.
Dr Keith E Wilson brings to Oxford BioTherapeutics over 20 years’ experience of life sciences research and development, specializing in oncology and immunology. He has extensive experience of developing and executing novel discovery, clinical and portfolio strategies, as well as providing executive-level support for corporate and business development activities.
In his most recent role, he was Director, Biologics Technology and Global Leader, Antibody Drug Conjugates at AbbVie, where he was responsible for corporate ADC strategy with multiple programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team.
Previously, he was Senior Director of Research at Facet Biotech, prior to which he was Director, Pipeline Strategy / Early Discovery and Computational Biology at PDL BioPharma. He also held positions of increasing seniority at EOS Biotechnology, where he began his industry career as a scientist.
Dr Wilson holds a PhD in Biochemistry and Molecular Biology from the Oregon Health Sciences University, and conducted post-doctoral research at Stanford University.
“I am delighted that Keith has chosen to join Oxford BioTherapeutics, where his world-class experience in leading ADC development programs will prove invaluable as we advance our pipeline into the clinic,” said Dr Christian Rohlff, Oxford BioTherapeutics’ CEO.
Commenting on his appointment, Dr Keith E Wilson, Oxford BioTherapeutics’ CSO, said, “I am highly impressed by the progress Oxford BioTherapeutics has made with its ADC programs, both scientifically and with the range and quality of the company’s technology collaborations and development partnerships. I look forward to helping the team continue this success as the company progresses its candidates into clinical development.”